The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Novocure to launch Optune Lua in Japan with national reimbursement coverage Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for ...
In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...
The 2-THE-TOP trial showed improved survival with Temodar, TTFields and Keytruda in glioblastoma patients compared to controls. Biopsy-only patients demonstrated longer progression-free and overall ...
Despite an expected 7% revenue growth for FY2025, NVCR stock price was cut in half in 2025 following the disappointing adoption of Optune Lua in the US and Germany. Yet, the company pipeline has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results